Systematic review and meta-analysis on microRNAs in amyotrophic lateral sclerosis

• Published in: Brain research bulletin Vol. 194; pp. 82 - 89
• Main Authors: Liu, Hua, Lan, Shan, Shi, Xiao-Jie, Fan, Fang-Cheng, Liu, Qing-Shan, Cong, Lin, Cheng, Yong
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2023
• Subjects: ALS; Amyotrophic Lateral Sclerosis - genetics; Biomarker; Biomarkers; Humans; Meta-analysis; MicroRNAs - genetics; MicroRNAs - metabolism; MiRNAs; Systematic review; ALS; MiRNAs; Systematic review; Biomarker; Meta-analysis
• ISSN: 0361-9230; 1873-2747; 1873-2747
• DOI: 10.1016/j.brainresbull.2023.01.005

MicroRNAs (miRNAs) exhibit a crucial role in the pathogenesis and progress of neurodegenerative disorders. Recent studies have shown abnormal levels of miRNA expression in patients with amyotrophic lateral sclerosis (ALS). Clinical data also confirmed that miRNAs in these patients are inconsistent across studies. A comprehensive systematic review and meta-analysis of current studies can help recognize the important roles of miRNAs during ALS development. Therefore, we initially aimed to perform a systematic literature review on the muscle or serum miRNAs in patients with ALS and healthy individuals. Subsequently, we quantitatively summarized the clinical data of muscle or serum miRNA of patients with ALS and healthy individuals using a meta-analytical technique. 11 studies comprising 281 patients with ALS and 244 healthy control (HC) controls were identified from PubMed and Web of Science for meta-analysis. A systematic review revealed that miRNA levels are closely associated with the occurrence of ALS disease. The expression levels of the most relevant miRNAs were either increased or decreased. The random-effects meta-analysis indicated that the levels of miR-206, miR-133b, and miR-338–3p were significantly elevated in patients with ALS than in HC subjects. By contrast, there was no significant differences in the miR-133a levels between patients with ALS and HC subjects. Collectively, our outcomes demonstrated that serum miR-206, miR-133b, and miR-338–3p were significantly increased in patients with ALS. We speculated that the increased expression levels of miR-206, miR-133b and miR-338–3p are potential promising biomarkers for ALS. •The levels of miR-206, miR-133b, and miR-338–3p were significantly elevated in patients with ALS than in HC subjects.•The levels of miR-206 in serum or muscle were significantly elevated in patients with ALS.•Increasing expression levels of miR-206, miR-133b and miR-338–3p are potential promising biomarkers for ALS.